Patents by Inventor Manuel Baca

Manuel Baca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Interleukin-2 variant proteins fused to human IgG4 Fc and uses thereof
    Patent number: 11896648
    Abstract: Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2R? (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: February 13, 2024
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Manuel Baca, Sarah A. Gilmore, Hassan Javanbakht, Prasenjit K. Mukherjee
  • COMPOSITIONS COMPRISING A TN3 SCAFFOLD AND METHODS OF USING THE SAME
    Publication number: 20230242619
    Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
    Type: Application
    Filed: November 1, 2022
    Publication date: August 3, 2023
    Inventors: Anthony COYLE, Manuel BACA, Thomas THISTED, Stacey DRABIC, Luba GRINBERG, Shabazz NOVARRA, Vaheh OGANESYAN, Ronald HERBST, David Kenneth SPENCER
  • MULTI-SPECIFIC ANTIGEN BINDING MOLECULES TARGETING HIV AND METHODS OF USE
    Publication number: 20230056252
    Abstract: Provided are multi-specific antigen binding molecules, including bispecific antibodies, that bind to CD3 and an HIV antigen, including HIV envelope protein gp120. Also provided are methods of using such antigen binding molecules to treat or prevent HIV infection.
    Type: Application
    Filed: August 23, 2021
    Publication date: February 23, 2023
    Inventors: Manuel Baca, Wade S. Blair, Brian A. Carr, Sheila B. Clancy, Joshua Goldsmith, Magdeleine S. Hung, Manu Kanwar, Brian Moldt, Mark Nagel, Craig S. Pace, YenRu Pan, Heather T. Stephenson, Nathan D. Thomsen
  • Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomer
    Patent number: 11555062
    Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: January 17, 2023
    Assignee: Viela Bio, Inc.
    Inventors: Anthony Coyle, Manuel Baca, Thomas Thisted, Stacey Drabic, Luba Grinberg, Shabazz Novarra, Vaheh Oganesyan, Ronald Herbst, David Kenneth Spencer
  • INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20220125884
    Abstract: Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2R? (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.
    Type: Application
    Filed: October 20, 2021
    Publication date: April 28, 2022
    Inventors: Manuel Baca, Sarah A. Gilmore, Magdeleine S. Hung, Hassan Javanbakht, Manu Kanwar, Shahzada Khan, Prasenjit K. Mukherjee, Mark R. Nagel, Giuseppe Papalia, Danny W. Tam, Majlinda K. Thomas
  • NUCLEIC ACIDS ENCODING A TN3 SCAFFOLD COMPRISING A CD40L-SPECIFIC MONOMER SUBUNIT
    Publication number: 20220089688
    Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
    Type: Application
    Filed: July 28, 2021
    Publication date: March 24, 2022
    Applicant: Viela Bio, Inc.
    Inventors: Anthony COYLE, Manuel BACA, Thomas THISTED, Stacey DRABIC, Luba GRINBERG, Shabazz NOVARRA, Vaheh OGANESYAN, Ronald HERBST, David SPENCER
  • FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20220049021
    Abstract: Provided are FLT3L-Fc fusion proteins, polynucleotides encoding such fusion proteins, expression cassettes, vectors, cells and kits comprising such fusion proteins, and methods of using.
    Type: Application
    Filed: August 18, 2021
    Publication date: February 17, 2022
    Inventors: Alexandre Ambrogelly, Manuel Baca, Brian A. Carr, Hon Man Hamlet Chu, Magdeleine S. Hung, Manu Kanwar, Michelle R. Kuhne, Douglas S. Rehder, Matthew R. Schenauer, Nicholas S. Wilson
  • FLT3L-FC fusion proteins
    Patent number: 11124582
    Abstract: Provided are FLT3L-Fc fusion proteins, polynucleotides encoding such fusion proteins, expression cassettes, vectors, cells and kits comprising such fusion proteins, and methods of using.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: September 21, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Alexandre Ambrogelly, Manuel Baca, Brian A. Carr, Hon Man Hamlet Chu, Magdeleine S. Hung, Manu Kanwar, Michelle R. Kuhne, Douglas S. Rehder, Matthew R. Schenauer, Nicholas S. Wilson
  • CD40L-Fc FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20210260159
    Abstract: Provided herein is a CD40L-Fc fusion protein and methods of using the fusion protein in the treatment of cancer comprising administering the CD40L-Fc fusion protein or the CD40L-Fc fusion protein in combination with one or more immune checkpoint inhibitors (e.g., an anti-CTLA4 antibody, anti-PD-L1 antibody).
    Type: Application
    Filed: March 8, 2021
    Publication date: August 26, 2021
    Inventors: MANUEL BACA, STACEY DRABIC, PETER EMTAGE, RONALD HERBST
  • Uricase sequences and methods of treatment
    Patent number: 11098289
    Abstract: Described are improved uricase sequences having beneficial effects and methods of treating patients suffering from hyperuricemia.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: August 24, 2021
    Assignee: MedImmune, LLC
    Inventors: Manuel Baca, Andrew C. Nyborg
  • URICASE SEQUENCES AND METHODS OF TREATMENT
    Publication number: 20210254024
    Abstract: Described are improved uricase sequences having beneficial effects and methods of treating patients suffering from hyperuricemia.
    Type: Application
    Filed: November 18, 2020
    Publication date: August 19, 2021
    Inventors: Manuel BACA, Andrew C. NYBORG
  • CD40L-Fc fusion polypeptides and methods of use thereof
    Patent number: 10975155
    Abstract: Provided herein is a CD40L-Fc fusion protein and methods of using the fusion protein in the treatment of cancer comprising administering the CD40L-Fc fusion protein or the CD40L-Fc fusion protein in combination with one or more immune checkpoint inhibitors (e.g., an anti-CTLA4 antibody, anti-PD-L1 antibody).
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: April 13, 2021
    Assignee: MEDIMMUNE, LLC
    Inventors: Manuel Baca, Stacey Drabic, Peter Emtage, Ronald Herbst
  • FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20210070887
    Abstract: Provided are FLT3L-Fc fusion proteins, polynucleotides encoding such fusion proteins, expression cassettes, vectors, cells and kits comprising such fusion proteins, and methods of using.
    Type: Application
    Filed: November 18, 2020
    Publication date: March 11, 2021
    Inventors: Alexandre Ambrogelly, Manuel Baca, Brian A. Carr, Hon Man Hamlet Chu, Magdeleine S. Hung, Manu Kanwar, Michelle R. Kuhne, Douglas S. Rehder, Matthew R. Schenauer, Nicholas S. Wilson
  • ANTIBODIES AGAINST G-CSFR AND USES THEREOF
    Publication number: 20210009701
    Abstract: The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.
    Type: Application
    Filed: July 9, 2020
    Publication date: January 14, 2021
    Applicant: CSL LIMITED
    Inventors: Andrew Donald Nash, Arna Elizabeth Andrews, Manuel Baca, Kirsten Mae Edwards, Matthew Philip Hardy, Con Panousis, Felicity Meredith Dunlop
  • FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20210009718
    Abstract: Provided are FLT3L-Fc fusion proteins, polynucleotides encoding such fusion proteins, expression cassettes, vectors, cells and kits comprising such fusion proteins, and methods of using.
    Type: Application
    Filed: June 23, 2020
    Publication date: January 14, 2021
    Inventors: Alexandre Ambrogelly, Manuel Baca, Brian A. Carr, Hon Man Hamlet Chu, Magdeleine S. Hung, Manu Kanwar, Michelle R. Kuhne, Douglas S. Rehder, Matthew R. Schenauer, Nicholas S. Wilson
  • Uricase sequences and methods of treatment
    Patent number: 10883087
    Abstract: Described are improved uricase sequences having beneficial effects and methods of treating patients suffering from hyperuricemia.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: January 5, 2021
    Assignee: MedImmune, LLC
    Inventors: Manuel Baca, Andrew C. Nyborg
  • ANTIBODIES AGAINST G-CSFR AND USES THEREOF
    Publication number: 20190055313
    Abstract: The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.
    Type: Application
    Filed: August 24, 2018
    Publication date: February 21, 2019
    Applicant: CSL LIMITED
    Inventors: Andrew Donald Nash, Arna Elizabeth Andrews, Manuel Baca, Kirsten Mae Edwards, Matthew Philip Hardy, Con Panousis, Felicity Meredith Dunlop
  • URICASE SEQUENCES AND METHODS OF TREATMENT
    Publication number: 20190048327
    Abstract: Described are improved uricase sequences having beneficial effects and methods of treating patients suffering from hyperuricemia.
    Type: Application
    Filed: October 23, 2018
    Publication date: February 14, 2019
    Inventors: Manuel BACA, Andrew C. NYBORG
  • High affinity antibody antagonists of interleukin-13 receptor alpha 1
    Patent number: 10106617
    Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: October 23, 2018
    Assignee: CSL LIMITED
    Inventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
  • Improved Uricase Sequences and Methods of Treatment
    Publication number: 20180258406
    Abstract: Described are improved uricase sequences having beneficial effects and methods of treating patients suffering from hyperuricemia.
    Type: Application
    Filed: May 13, 2016
    Publication date: September 13, 2018
    Inventors: Manuel Baca, Andrew C. NYBORG